New York, NY – According to filings with the U.S. Securities and Exchange Commission, Cambrian BioPharma is raising $100,775,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Peyer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cambrian BioPharma
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

To learn more about Cambrian BioPharma, visit http://www.cambrianbio.com/

Contact:
James Peyer, Chief Executive Officer
516-962-3186
https://www.linkedin.com/in/jamespeyer/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved